



FLORIDA MEDICAID PRIOR AUTHORIZATION

OPIOID AGENTS

LENGTH OF APPROVAL: UP TO 3 MONTHS

Note: Form must be completed in full. An incomplete form may be returned.

Recipient's Full Name:

Grid for recipient's full name.

Recipient's Medicaid ID#:

Grid for recipient's Medicaid ID number.

Date of Birth (MM/DD/YYYY):

Grid for date of birth in MM/DD/YYYY format.

Prescriber's Full Name:

Grid for prescriber's full name.

Prescriber's NPI:

Grid for prescriber's NPI number.

Prescriber Phone Number:

Grid for prescriber phone number with hyphens.

Prescriber Fax Number:

Grid for prescriber fax number with hyphens.

- Short-Acting Opioid, Long-Acting Opioid, Both checkboxes.

Drug Name: _____

Drug Strength: _____

Dose: _____

Directions: _____

Diagnosis: _____

Prescriber's Specialty (or consultation with a specialist): _____

- 1. There was a trial and failure of the following medication(s) prior to prescribing short-acting opioids (check all that apply):
- [] Baclofen [] NSAIDs (oral) [] Tricyclic antidepressant (e.g., amitriptyline)
- [] Lyrica [] Duloxetine [] Other: _____

- Any requests for post-operative, short-acting opioids cannot exceed a 7-day supply without medical justification.
Long-acting opioids are indicated for patients with chronic, moderate to severe pain who require around-the-clock opioid analgesics. Supporting documentation of a minimum two-month trial of short-acting opioid use is required.

2. If the request is for a non-preferred agent, trial and failure of preferred agents is required. Medical records documenting trials are also required. List the names of the medications, strength, frequency, length of trials, and rationale for discontinuation.

3. What is the daily morphine milligram equivalent (MME) of the prescribed medication(s)? _____
If patient is treatment-naïve (MME exceeding 90), PA will not be approved.



FLORIDA MEDICAID PRIOR AUTHORIZATION

OPIOID AGENTS

LENGTH OF APPROVAL: UP TO 3 MONTHS

Note: Form must be completed in full.

An incomplete form may be returned.

Recipient's Full Name

Grid for recipient's full name

4. Did the prescriber review the Prescribed Drug Monitoring Program prior to prescribing this opioid medication as required by Florida statute?

Yes No

a. If NO, explain why:

- Submission of a signed patient-prescriber pain management, opioid treatment agreement is required for chronic pain patients

5. When is the next office visit scheduled for the patient with chronic pain? Date:

6. Has the prescriber ordered and reviewed a urine drug screen (UDS) for new chronic pain patients prior to initiation of opioid therapy? (Submission of a UDS within the past 90 days is required.)

Yes No

a. If NO, explain why:

Continuation of Ongoing Therapy

1. Has the prescriber ordered and reviewed a UDS for patients with chronic pain to ensure compliance of opioid therapy? (Submission of a UDS within the past 90 days is required.)

Yes No

2. When is the next office visit scheduled for the patient with chronic pain? Date:

3. If requesting an increase in dose or frequency, calculate the new daily morphine milligram equivalent (MME) of the prescribed medication(s) and provide rationale for why this dose is medically necessary.

****Clinicians should consider offering naloxone to patients with an increased risk of opioid overdose.****

I certify that the benefits of opioid treatment for this patient outweigh the risk of treatment.

Prescriber's Signature: Date:

REQUIRED FOR REVIEW: All copies of medical records (e.g., diagnostic evaluations and recent chart notes) and the most recent copies of related labs. The provider must retain copies of all documentation for five years.

Mail or Fax Information to: Magellan Medicaid Administration, Inc. Prior Authorization P. O. Box 7082 Tallahassee, FL 32314-7082 Phone: 877-553-7481 Fax: 877-614-1078

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.